Navigation Links
OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
Date:6/4/2013

STOCKHOLM, June 4, 2013 /PRNewswire/ --

OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and will further strengthen the Company's patent estate for this unmet medical need.

"We are continuously working to further strengthen the world-wide rights for our lead product Oxabact®" for treatment of Primary Hyperoxaluria, an orphan disease," says Elisabeth Lindner , CEO of OxThera. "The Japanese rights are important additions to our already granted patents in the EU and the US. Japan is an important market for hyperoxaluria" Elisabeth Lindner continues.

OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in seven patent families with approximately eighty applications filed. The new granted Japanese patents have numbers 4996780, 5047190 and 5203217.

Oxabact® is an oral product composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes), administered in capsules. The drug is designed for delivery in the lower part of the small intestine, where enteric elimination of endogenous oxalate is initiated. OxThera is currently pursuing a complete Oxabact® clinical development plan in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.

About Primary Hyperoxaluria

Primary Hyperoxaluria is a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including kidney stone formation and/or calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death. There is a high medical need for effective treatments of Primary Hyperoxaluria. Currently, the only available cure is a combined liver and kidney transplantation.

Oxabact® holds orphan drug designations in the EU and the US for the treatment of Primary Hyperoxaluria.

About OxThera

OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for the prevention of oxalate malabsorption and recurring kidney stones in Secondary Hyperoxaluria. OxThera operates through the head office in Stockholm, Sweden, and its subsidiary OxThera Inc. in Alachua, Florida, USA.

For further information, please contact Elisabeth Lindner , CEO of OxThera AB, Phone +46-8-660-02-23


http://www.oxthera.com


'/>"/>
SOURCE OxThera
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
2. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
3. RxAlly Strengthens Leadership Team With New Chief Information Officer Mike Groh
4. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
5. Actinium Pharmaceuticals Strengthens Management Team
6. Pharmalink AB Strengthens Senior Management Team
7. Jardogs Strengthens Leadership Team with the Addition of Two Seasoned Healthcare Executives
8. inVentiv Health Strengthens Clinical Leadership Team
9. Alliqua Strengthens and Realigns Executive Team
10. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
11. TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its ... also filed its Quarterly Report on Form 10-Q for the ... Exchange Commission today. --> --> ... --> Net sales for the three months ... $5.4 million from $2.8 million for the three months ended ...
(Date:2/11/2016)... 11, 2016  Walgreens has committed to provide drug ... Washington, D.C. as part of a ... commended by shareholder advocacy organization As You Sow. ... "Many people hold on to unneeded drugs because they lack ... consequences." --> Conrad MacKerron , Senior Vice ...
(Date:2/11/2016)... Feb. 11, 2016 Potrero Medical, Inc., the developer ... announce the appointment of George M. Rapier, III , ... Antonio, TX , WellMed is one of the nation,s ... and HMO members in Texas and ... out of his own internal medicine practice, he has been ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... , ... AssureVest Insurance Group, a locally owned insurance firm with offices serving ... funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd and 3rd grade ... a low-income area and has more than 60 2nd and 3rd graders with learning ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Erlanger Agency ... the greater Columbus, OH area. The latest campaign focuses on the fight against breast ... Donations are now being accepted here . , Carmen is a loving single ...
(Date:2/12/2016)... ... 2016 , ... Miami Dental Specialists is excited to bring patients the choice ... in January, Miami Dental Specialists will offer the non-metal implants as a safe, holistic ... be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today ... , The print component of “Revolutionizing Cancer Care” is distributed within the February ... and Seattle, with a circulation of approximately 250,000 copies and an estimated readership ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now ... design possibilities. CertainTeed, North America’s leading brand of building products, has improved upon ... showcased in the mobile version of the ColorView® Exterior Style and Color Selector. ...
Breaking Medicine News(10 mins):